Rx Product News (March 2017)

MARCH 20, 2017

RHOFADE
MARKETED BY:
Allergan
INDICATION: Allergan has announced the FDA approval of Rhofade cream, which is indicated for the topical treatment of persistent facial erythema (redness) associated with rosacea in adults.
DOSAGE FORM: Topical cream: once-daily application
FOR MORE INFORMATION: allergan.com


NARCAN NASAL SPRAY
MARKETED BY:
Adapt Pharma
INDICATION: The FDA has approved Narcan Nasal Spray (concentrated naloxone) as a 2-mg formulation for the emergency treatment of known or suspected opioid abuse, as manifested by respiratory and/or central nervous system depression.
DOSAGE FORM: Nasal spray: 2 and 4 mg
FOR MORE INFORMATION: adaptpharma.com


LINZESS
MARKETED BY:
Ironwood and Allergan
INDICATION: The FDA has approved a 72-mcg dose of Linzess (linaclotide) for the treatment of chronic idiopathic constipation (CIC) in adult patients. Linzess is now approved in 3 dosage strengths: 290 mcg for adult patients with irritable bowel syndrome with constipation, and 145 mcg and the new 72 mcg for adults with CIC.
DOSAGE FORM: Capsules: 72, 145, and 290 mcg
FOR MORE INFORMATION: allergan.com


EMFLAZA
MARKETED BY:
Marathon Pharmaceuticals, LLC
INDICATION: The FDA has approved Emflaza (deflazacort) tablets and oral suspension for the treatment of Duchenne muscular dystrophy in patients 5 years and older.
DOSAGE FORM: Tablets (6, 18, 30, and 36 mg) and oral suspension (22.75 mg/mL)
FOR MORE INFORMATION: emflaza.com

SHARE THIS SHARE THIS
1
Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.